Cargando…

Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis

The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontana, Marianna, Pica, Silvia, Reant, Patricia, Abdel-Gadir, Amna, Treibel, Thomas A., Banypersad, Sanjay M., Maestrini, Viviana, Barcella, William, Rosmini, Stefania, Bulluck, Heerajnarain, Sayed, Rabya H., Patel, Ketna, Mamhood, Shameem, Bucciarelli-Ducci, Chiara, Whelan, Carol J., Herrey, Anna S., Lachmann, Helen J., Wechalekar, Ashutosh D., Manisty, Charlotte H., Schelbert, Eric B., Kellman, Peter, Gillmore, Julian D., Hawkins, Philip N., Moon, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606985/
https://www.ncbi.nlm.nih.gov/pubmed/26362631
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016567
_version_ 1782395449173344256
author Fontana, Marianna
Pica, Silvia
Reant, Patricia
Abdel-Gadir, Amna
Treibel, Thomas A.
Banypersad, Sanjay M.
Maestrini, Viviana
Barcella, William
Rosmini, Stefania
Bulluck, Heerajnarain
Sayed, Rabya H.
Patel, Ketna
Mamhood, Shameem
Bucciarelli-Ducci, Chiara
Whelan, Carol J.
Herrey, Anna S.
Lachmann, Helen J.
Wechalekar, Ashutosh D.
Manisty, Charlotte H.
Schelbert, Eric B.
Kellman, Peter
Gillmore, Julian D.
Hawkins, Philip N.
Moon, James C.
author_facet Fontana, Marianna
Pica, Silvia
Reant, Patricia
Abdel-Gadir, Amna
Treibel, Thomas A.
Banypersad, Sanjay M.
Maestrini, Viviana
Barcella, William
Rosmini, Stefania
Bulluck, Heerajnarain
Sayed, Rabya H.
Patel, Ketna
Mamhood, Shameem
Bucciarelli-Ducci, Chiara
Whelan, Carol J.
Herrey, Anna S.
Lachmann, Helen J.
Wechalekar, Ashutosh D.
Manisty, Charlotte H.
Schelbert, Eric B.
Kellman, Peter
Gillmore, Julian D.
Hawkins, Philip N.
Moon, James C.
author_sort Fontana, Marianna
collection PubMed
description The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying risk is unknown. METHODS AND RESULTS—: Two hundred fifty prospectively recruited subjects, 122 patients with ATTR amyloid, 9 asymptomatic mutation carriers, and 119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance. Subjects were followed up for a mean of 24±13 months. LGE was performed with phase-sensitive inversion recovery (PSIR) and without (magnitude only). These were compared with extracellular volume measured with T1 mapping. PSIR was superior to magnitude-only inversion recovery LGE because PSIR always nulled the tissue (blood or myocardium) with the longest T1 (least gadolinium). LGE was classified into 3 patterns: none, subendocardial, and transmural, which were associated with increasing amyloid burden as defined by extracellular volume (P<0.0001), with transitions from none to subendocardial LGE at an extracellular volume of 0.40 to 0.43 (AL) and 0.39 to 0.40 (ATTR) and to transmural at 0.48 to 0.55 (AL) and 0.47 to 0.59 (ATTR). Sixty-seven patients (27%) died. Transmural LGE predicted death (hazard ratio, 5.4; 95% confidence interval, 2.1–13.7; P<0.0001) and remained independent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke volume index, E/E′, and left ventricular mass index (hazard ratio, 4.1; 95% confidence interval, 1.3–13.1; P<0.05). CONCLUSIONS—: There is a continuum of cardiac involvement in systemic AL and ATTR amyloidosis. Transmural LGE is determined reliably by PSIR and represents advanced cardiac amyloidosis. The PSIR technique provides incremental information on outcome even after adjustment for known prognostic factors.
format Online
Article
Text
id pubmed-4606985
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-46069852015-10-29 Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis Fontana, Marianna Pica, Silvia Reant, Patricia Abdel-Gadir, Amna Treibel, Thomas A. Banypersad, Sanjay M. Maestrini, Viviana Barcella, William Rosmini, Stefania Bulluck, Heerajnarain Sayed, Rabya H. Patel, Ketna Mamhood, Shameem Bucciarelli-Ducci, Chiara Whelan, Carol J. Herrey, Anna S. Lachmann, Helen J. Wechalekar, Ashutosh D. Manisty, Charlotte H. Schelbert, Eric B. Kellman, Peter Gillmore, Julian D. Hawkins, Philip N. Moon, James C. Circulation Original Articles The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying risk is unknown. METHODS AND RESULTS—: Two hundred fifty prospectively recruited subjects, 122 patients with ATTR amyloid, 9 asymptomatic mutation carriers, and 119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance. Subjects were followed up for a mean of 24±13 months. LGE was performed with phase-sensitive inversion recovery (PSIR) and without (magnitude only). These were compared with extracellular volume measured with T1 mapping. PSIR was superior to magnitude-only inversion recovery LGE because PSIR always nulled the tissue (blood or myocardium) with the longest T1 (least gadolinium). LGE was classified into 3 patterns: none, subendocardial, and transmural, which were associated with increasing amyloid burden as defined by extracellular volume (P<0.0001), with transitions from none to subendocardial LGE at an extracellular volume of 0.40 to 0.43 (AL) and 0.39 to 0.40 (ATTR) and to transmural at 0.48 to 0.55 (AL) and 0.47 to 0.59 (ATTR). Sixty-seven patients (27%) died. Transmural LGE predicted death (hazard ratio, 5.4; 95% confidence interval, 2.1–13.7; P<0.0001) and remained independent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke volume index, E/E′, and left ventricular mass index (hazard ratio, 4.1; 95% confidence interval, 1.3–13.1; P<0.05). CONCLUSIONS—: There is a continuum of cardiac involvement in systemic AL and ATTR amyloidosis. Transmural LGE is determined reliably by PSIR and represents advanced cardiac amyloidosis. The PSIR technique provides incremental information on outcome even after adjustment for known prognostic factors. Lippincott Williams & Wilkins 2015-10-20 2015-10-19 /pmc/articles/PMC4606985/ /pubmed/26362631 http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016567 Text en © 2015 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
spellingShingle Original Articles
Fontana, Marianna
Pica, Silvia
Reant, Patricia
Abdel-Gadir, Amna
Treibel, Thomas A.
Banypersad, Sanjay M.
Maestrini, Viviana
Barcella, William
Rosmini, Stefania
Bulluck, Heerajnarain
Sayed, Rabya H.
Patel, Ketna
Mamhood, Shameem
Bucciarelli-Ducci, Chiara
Whelan, Carol J.
Herrey, Anna S.
Lachmann, Helen J.
Wechalekar, Ashutosh D.
Manisty, Charlotte H.
Schelbert, Eric B.
Kellman, Peter
Gillmore, Julian D.
Hawkins, Philip N.
Moon, James C.
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
title Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
title_full Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
title_fullStr Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
title_full_unstemmed Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
title_short Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
title_sort prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606985/
https://www.ncbi.nlm.nih.gov/pubmed/26362631
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016567
work_keys_str_mv AT fontanamarianna prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT picasilvia prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT reantpatricia prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT abdelgadiramna prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT treibelthomasa prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT banypersadsanjaym prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT maestriniviviana prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT barcellawilliam prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT rosministefania prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT bulluckheerajnarain prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT sayedrabyah prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT patelketna prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT mamhoodshameem prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT bucciarelliduccichiara prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT whelancarolj prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT herreyannas prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT lachmannhelenj prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT wechalekarashutoshd prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT manistycharlotteh prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT schelbertericb prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT kellmanpeter prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT gillmorejuliand prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT hawkinsphilipn prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis
AT moonjamesc prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis